Details of the Drug Reposition

General Information of This Drug (ID: DM2TEOL)

• Drug Name: Methotrexate (DM2TEOL)
• Synonyms: methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

15 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sensorineural hearing loss disorder	DISJV45Z	N.A.	Approved	[1]
Posterior urethra cancer	DIS3DNQW	N.A.	Approved	[1]
Leukemia	DISNAKFL	N.A.	Approved	[1]
Childhood acute lymphoblastic leukemia	DISJ5D6U	N.A.	Approved	[1]
Burkitt lymphoma	DIS9D5XU	N.A.	Approved	[1]
Anterior urethra cancer	DISAKHZJ	N.A.	Approved	[1]
Inflammation	DISJUQ5T	1A00-CA43.1	Approved	[1]
Mycosis fungoides	DIS62RB8	2B01	Approved	[1]
Lung cancer	DISCM4YA	2C25.0	Approved	[1]
Choriocarcinoma	DISDBVNL	2C75.0	Approved	[2]
Head and neck cancer	DISBPSQZ	2D42	Approved	[1]
Gestational trophoblastic neoplasia	DIS4EJNA	2F33-2F76	Approved	[1]
Psoriasis	DIS59VMN	EA90	Approved	[1]
Urticaria	DIS9WQAI	EB00-EB05	Approved	[1]
leukaemia	DISS7D1V	2A60-2B33	Approved	[3]

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 3	[3]
Proliferative vitreoretinopathy	DISZTEK1	9B78.2	Phase 3	[4]

1 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 1/2	[5]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ovarian cancer	DISZJHAP	2C73	Withdrawn	[6]

3 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ureter cancer	DISOUKYP	N.A.	Discontinued in Phase 3	[7]
Acute lymphocytic leukaemia	DISPX75S	2B33.3	Discontinued in Phase 3	[8]
Rheumatoid arthritis	DISTSB4J	FA20	Discontinued in Phase 3	[9]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bone osteosarcoma	DIST1004	N.A.	Discontinued in Phase 2	[10]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Prostate cancer	DISF190Y	2C82.0	Investigative	[11]

References

• [1] Methotrexate FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 040632.
• [3] Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for ... Trials. 2015 Mar 4;16:77.
• [4] ClinicalTrials.gov (NCT04136366) The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04352465) Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients. U.S. National Institutes of Health.
• [6] Penicillamine Chelation for Children With Lead Poisoning
• [7] A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
• [8] Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain
• [9] Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
• [10] Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis
• [11] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.